{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CPI&page=2",
    "query": {
      "intervention": "CPI",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CPI&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T00:07:06.224Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04909619",
      "title": "Suprazygomatic Maxillary Nerve Block in Cleft Palate Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cleft Palate Children"
      ],
      "interventions": [
        {
          "name": "Ultrasound-guided bilateral suprazygomatic maxillary nerve block",
          "type": "PROCEDURE"
        },
        {
          "name": "Local anesthetic infiltration of the palate",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Months",
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "9 Months to 2 Years"
      },
      "enrollment_count": 40,
      "start_date": "2021-03-01",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04909619"
    },
    {
      "nct_id": "NCT05419245",
      "title": "Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Freeman-Burian Syndrome",
        "Freeman-Sheldon Syndrome",
        "Whistling Face Syndrome",
        "Sheldon-Hall Syndrome",
        "Freeman-Sheldon Syndrome Variant",
        "Arthrogryposis Distal Type 1",
        "Arthrogryposis Distal Type 3",
        "Gordon Syndrome"
      ],
      "interventions": [
        {
          "name": "Guided Health History for Freeman-Burian Syndrome Questionnaire",
          "type": "OTHER"
        },
        {
          "name": "Freeman-Burian syndrome Semi-Structured Quality of Life Interview",
          "type": "OTHER"
        },
        {
          "name": "Medical Records Review",
          "type": "OTHER"
        },
        {
          "name": "PTSD Checklist for DSM-5",
          "type": "OTHER"
        },
        {
          "name": "Modified Flanagan Quality of Life Scale",
          "type": "OTHER"
        },
        {
          "name": "Center for Epidemiologic Studies Depression Scale",
          "type": "OTHER"
        },
        {
          "name": "Review of Systems",
          "type": "OTHER"
        },
        {
          "name": "FACE-Q | Craniofacial - Appearance of the Face",
          "type": "OTHER"
        },
        {
          "name": "FACE-Q | Craniofacial - Appearance Distress",
          "type": "OTHER"
        },
        {
          "name": "FACE-Q | Craniofacial - Facial Function",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dufresne, Craig, MD, PC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2022-06-01",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2022-07-19",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05419245"
    },
    {
      "nct_id": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Resectable Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "INBRX-106 - Hexavalent OX40 agonist antibody",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 200 mg",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-5",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-6",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed 500 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin 75mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel 200mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel 100mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (1000 mg/m2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2019-12-10",
      "completion_date": "2033-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04198766"
    },
    {
      "nct_id": "NCT00341068",
      "title": "Genetic Analysis of Neural Tube and Orofacial Cleft Defects in the Irish Population",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neural Tube Defects (NTDs)",
        "Facial Cleft Defect",
        "Hereditary Oral Clefts"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "Up to 85 Years"
      },
      "enrollment_count": 7451,
      "start_date": "2000-01-01",
      "completion_date": "2019-12-02",
      "has_results": false,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00341068"
    },
    {
      "nct_id": "NCT03708328",
      "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Metastatic Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Small Cell Lung Cancer (SCLC)",
        "Esophageal Squamous Cell Carcinoma (ESCC)"
      ],
      "interventions": [
        {
          "name": "Lomvastomig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2018-10-15",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03708328"
    },
    {
      "nct_id": "NCT03468426",
      "title": "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-squamous, Non-Small-Cell Lung Cancer",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BI 836880",
          "type": "DRUG"
        },
        {
          "name": "Ezabenlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2018-07-05",
      "completion_date": "2024-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468426"
    },
    {
      "nct_id": "NCT01301950",
      "title": "Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Custom Patient Instrumentation",
          "type": "OTHER"
        },
        {
          "name": "Conventional Instruments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "DePuy Orthopaedics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-05-01",
      "completion_date": "2013-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 3,
      "location_summary": "Mooresville, Indiana • Bartlesville, Oklahoma • Reston, Virginia",
      "locations": [
        {
          "city": "Mooresville",
          "state": "Indiana"
        },
        {
          "city": "Bartlesville",
          "state": "Oklahoma"
        },
        {
          "city": "Reston",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01301950"
    },
    {
      "nct_id": "NCT03785925",
      "title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasm",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Bempegaldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2019-04-29",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-28",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Whittier, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03785925"
    },
    {
      "nct_id": "NCT03809624",
      "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Non-small Cell Lung Cancer",
        "Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Renal Cell Carcinoma",
        "Esophageal Adenocarcinoma",
        "Nasopharyngeal Carcinoma",
        "Oropharyngeal Carcinoma"
      ],
      "interventions": [
        {
          "name": "INBRX-105 - PDL1x41BB antibody",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2019-01-30",
      "completion_date": "2024-10-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 23,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03809624"
    },
    {
      "nct_id": "NCT07219901",
      "title": "Early Intervention in Infants With Unrepaired Cleft Palate: Language, Palatal Function, and Articulation.",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cleft Lip and Cleft Palate",
        "Cleft Lip Palate",
        "Cleft Lip and/or Palate",
        "Cleft Palate",
        "Cleft Palate Children",
        "Cleft Palates",
        "Cleft Palate Repair"
      ],
      "interventions": [
        {
          "name": "Early intervention for language, articulation and palatal function skills",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Old Dominion University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "6 Months to 12 Months"
      },
      "enrollment_count": 200,
      "start_date": "2025-10-21",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-09-05T00:07:06.224Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219901"
    }
  ]
}